Kyongbo Pharmaceutical Co Ltd (214390) — Cash Flow Reinvestment Rate
Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow Reinvestment Rate of 11.05x as of March 2026, reinvesting ₩19.76 Billion (capex ₩15.55 Billion plus investments ₩-4.21 Billion) from operating cash flow of ₩1.79 Billion. See 214390 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Kyongbo Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2014–2025)
Historical reinvestment intensity for Kyongbo Pharmaceutical Co Ltd across 11 annual periods. For the full cash flow conversion analysis, see how efficiently does Kyongbo Pharmaceutical Co Ltd generate cash.
Annual Cash Flow Reinvestment Rate for Kyongbo Pharmaceutical Co Ltd (2014–2025)
Year-by-year capital reinvestment analysis for Kyongbo Pharmaceutical Co Ltd. See 214390 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 5.74x | ₩42.82 Billion | ₩7.46 Billion | ₩41.61 Billion | ▼ -94.0% |
| 2024 | 95.93x | ₩14.31 Billion | ₩149.12 Million | ₩13.18 Billion | ▲ +3205.3% |
| 2023 | 2.90x | ₩14.06 Billion | ₩4.84 Billion | ₩10.88 Billion | ▲ +4.7% |
| 2022 | 2.77x | ₩28.06 Billion | ₩10.13 Billion | ₩13.18 Billion | ▲ +143.5% |
| 2021 | 1.14x | ₩20.45 Billion | ₩17.97 Billion | ₩18.32 Billion | ▲ +20.5% |
| 2020 | 0.94x | ₩19.63 Billion | ₩20.80 Billion | ₩12.44 Billion | ▼ -18.6% |
| 2019 | 1.16x | ₩27.45 Billion | ₩23.67 Billion | ₩23.25 Billion | ▲ +256.4% |
| 2017 | 0.33x | ₩8.40 Billion | ₩25.81 Billion | ₩7.40 Billion | ▼ -79.3% |
| 2016 | 1.57x | ₩39.84 Billion | ₩25.33 Billion | ₩19.68 Billion | ▼ -76.0% |
| 2015 | 6.56x | ₩27.80 Billion | ₩4.24 Billion | ₩27.26 Billion | ▲ +423.9% |
| 2014 | 1.25x | ₩20.08 Billion | ₩16.04 Billion | ₩19.28 Billion | — |